biostudies-literatureIbrahim SLIraqi Cultural Attaché in London (Iraqi Cultural Attaché - London)North Staffordshire medical institute, Staffordshire No grant reference number.Iraqi Cultural Attaché in LondonHigher Committee for Education Development in Iraq (HCED)Higher Committee for Education Development in Iraq896-906https://www.ebi.ac.uk/biostudies/studies/S-EPMC9977917biostudies-literatureUnknown128(5)<h4>Context</h4>Many cancer patients who initially respond to chemotherapy eventually develop chemoresistance, and to address this, we previously conducted a RNAi screen to identify genes contributing to resistance. One of the hits from the screen was branched-chain α-keto acid dehydrogenase kinase (BCKDK). BCKDK controls the metabolism of branched-chain amino acids (BCAAs) through phosphorylation and inactivation of the branched-chain α-keto acid dehydrogenase complex (BCKDH), thereby inhibiting catabolism of BCAAs.<h4>Methods</h4>We measured the impact on paclitaxel sensitivity of inhibiting BCKDK in ovarian and breast cancer cell lines.<h4>Results</h4>Inhibition of BCKDK using siRNA or two chemical inhibitors (BCKDKi) was synergistic with paclitaxel in both breast and ovarian cancer celBritish journal of cancerInhibition of branched-chain alpha-keto acid dehydrogenase kinase augments the sensitivity of ovarian and breast cancer cells to paclitaxel.PMC9977917D-11-296S939S1442Richardson AIbrahim SLPrice JCAbdullah MIAbed MNMohamed GfalseInhibition of branched-chain alpha-keto acid dehydrogenase kinase augments the sensitivity of ovarian and breast cancer cells to paclitaxel.<h4>Context</h4>Many cancer patients who initially respond to chemotherapy eventually develop chemoresistance, and to address this, we previously conducted a RNAi screen to identify genes contributing to resistance. One of the hits from the screen was branched-chain α-keto acid dehydrogenase kinase (BCKDK). BCKDK controls the metabolism of branched-chain amino acids (BCAAs) through phosphorylation and inactivation of the branched-chain α-keto acid dehydrogenase complex (BCKDH), thereby inhibiting catabolism of BCAAs.<h4>Methods</h4>We measured the impact on paclitaxel sensitivity of inhibiting BCKDK in ovarian and breast cancer cell lines.<h4>Results</h4>Inhibition of BCKDK using siRNA or two chemical inhibitors (BCKDKi) was synergistic with paclitaxel in both breast and ovarian cancer cel2023-01-01T00:00:00Z2023 Mar2025-04-18T14:13:24.765Z2025-04-07T00:15:00.574ZS-EPMC99779173652667410.1038/s41416-022-02095-9